Eagle Pharmaceuticals, Inc. (EGRX) Cash Flow Statement
Where EGRX’s cash came from and went, 2022
December 31, 2022 · U.S. dollars- Cash from operations
- $50.7M +79.7% vs 2021
- Capital expenditures
- $178,000 0.1% of revenue
- Free cash flow
- $50.5M 16.0% margin
- Returned to shareholders
- $19.8M 39% of free cash flow
- Change in cash
- −$42.3M cash at year-end $55.3M
Drawn to scale: where the cash came from and how it was used. Hover for values.
EGRX operating cash flow, capex and free cash flow
EGRX cash flow trends, 2013–2022
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$5.9M2013 | $50.7M2022 | — | |
| Capital expenditures | $40,5482013 | $178,0002022 | +17.9%/yr | |
| Free cash flow | −$5.9M2013 | $50.5M2022 | — | |
| Free cash flow margin | −43.3%2013 | 16.0%2022 | +59.2 pts | |
| Operating cash flow / net income | −3.782015 | 1.422022 | +5.20 | |
| Stock-based compensation | $317,1922013 | $16.5M2022 | +55.1%/yr | |
| Dividends paid | $02014 | $1.7M2022 | — | |
| Share buybacks (net) | $02014 | $18.0M2022 | — | |
| Capex / revenue | 0.3%2013 | 0.1%2022 | −0.2 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
EGRX cash flow by activity
EGRX net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
EGRX cash flow statement
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | $35.6M | −$8.6M | $12.0M | $14.3M | $31.9M | $51.9M | $81.5M | $2.6M | −$18.0M | −$6.0M |
| Depreciation & amortization | $12.0M | $3.8M | $4.8M | $4.7M | $3.7M | $3.7M | $1.6M | $112,000 | $104,000 | $134,994 |
| Stock-based compensation | $16.5M | $19.6M | $24.8M | $22.0M | $19.1M | $15.4M | $9.8M | $4.1M | $606,000 | $317,192 |
| Change in working capital | −$16.4M | $9.5M | $816,000 | $14.4M | −$7.9M | −$29.6M | −$8.7M | −$16.7M | $2.9M | −$2.8M |
| Other non-cash items | $3.0M | $4.0M | $7.2M | $632,000 | $5.6M | $17.4M | −$30.9M | $273,000 | $573,000 | $2.5M |
| Cash from operating activities | $50.7M | $28.2M | $49.5M | $56.0M | $52.4M | $58.9M | $53.2M | −$9.7M | −$13.8M | −$5.9M |
| Investing activities | ||||||||||
| Capital expenditures | −$178,000 | −$323,000 | −$747,000 | −$777,000 | −$133,000 | −$5.2M | −$20.7M | −$1.9M | −$46,000 | −$40,548 |
| Investments (net) | −$86.8M | −$5.3M | −$18.2M | −$777,000 | −$133,000 | −$5.2M | −$45.8M | — | −$20.0M | — |
| Acquisitions & other investing | $178,000 | $323,000 | $747,000 | $777,000 | $133,000 | $5.2M | $20.7M | $0 | $0 | $1.5M |
| Cash from investing activities | −$86.8M | −$5.3M | −$18.2M | −$777,000 | −$133,000 | −$5.2M | −$45.8M | −$1.9M | −$20.0M | $1.5M |
| Financing activities | ||||||||||
| Dividends paid | −$1.7M | −$2.4M | −$3.7M | −$260,000 | — | $0 | $0 | $0 | $0 | — |
| Share repurchases & issuance (net) | −$18.0M | −$21.2M | −$35.0M | −$18.0M | −$73.1M | −$43.8M | −$37.0M | $55.8M | $46.2M | — |
| Net borrowing (repayment) | $11.4M | −$8.0M | −$5.0M | −$6.3M | −$3.8M | $47.6M | $48.8M | $48.8M | $48.8M | — |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | $2.1M | $3.2M | $5.8M | $322,000 | −$11.3M | $4.3M | −$45.4M | −$48.8M | −$48.8M | $9.8M |
| Cash from financing activities | −$6.2M | −$28.4M | −$37.9M | −$24.2M | −$88.1M | $8.1M | −$33.7M | $55.8M | $46.2M | $9.8M |
| Summary | ||||||||||
| Net change in cash | −$42.3M | −$5.5M | −$6.6M | $31.0M | −$35.9M | $61.8M | −$26.3M | $44.2M | $12.3M | $5.4M |
| Cash at end of period | $55.3M | $97.7M | $103.2M | $109.8M | $78.8M | $114.7M | $52.8M | $79.1M | $22.7M | $10.5M |
| Free cash flow | $50.5M | $27.9M | $48.8M | $55.2M | $52.3M | $53.7M | $32.5M | −$11.6M | −$13.9M | −$5.9M |
| Free cash flow margin | 16.0% | 16.3% | 26.0% | 28.2% | 24.5% | 22.7% | 17.2% | −17.5% | −72.7% | −43.3% |
| Capex / revenue | 0.1% | 0.2% | 0.4% | 0.4% | 0.1% | 2.2% | 10.9% | 2.8% | 0.2% | 0.3% |
| Operating cash flow / net income | 1.42 | — | 4.13 | 3.91 | 1.64 | 1.13 | 0.65 | −3.78 | — | — |
| Jun '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | Mar '22 | Dec '21 | Sep '21 | Jun '21 | Mar '21 | Dec '20 | Sep '20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | $5.2M | $5.8M | $8.2M | −$3.5M | −$9.4M | $44.1M | −$6.2M | −$5.6M | $3.6M | −$421,000 | $8.1M | $7.1M |
| Depreciation & amortization | $5.6M | $5.6M | $5.6M | $3.9M | $1.6M | $908,000 | $1.1M | $903,000 | $894,000 | $896,000 | $1.1M | $1.4M |
| Stock-based compensation | $4.2M | $4.6M | $4.1M | $3.5M | $4.5M | $4.3M | $4.7M | $4.1M | $4.3M | $6.5M | $6.3M | $4.7M |
| Change in working capital | −$14.2M | −$48.0M | $29.1M | −$24.5M | $44.7M | −$65.8M | $4.8M | $2.7M | −$5.7M | $7.7M | $6.0M | −$12.9M |
| Other non-cash items | −$830,000 | −$1.4M | −$9.5M | $7.3M | $1.6M | −$111,000 | $3.7M | −$1.0M | $5.5M | −$4.2M | −$1.7M | $5.4M |
| Cash from operating activities | −$126,000 | −$33.5M | $37.6M | −$13.2M | $43.0M | −$16.6M | $8.1M | $1.1M | $8.6M | $10.5M | $19.8M | $5.6M |
| Investing activities | ||||||||||||
| Capital expenditures | −$6,000 | −$58,000 | −$10,000 | −$10,000 | $0 | −$168,000 | −$49,000 | −$5,000 | −$115,000 | −$384,000 | −$170,000 | −$201,000 |
| Investments (net) | −$6,000 | −$12.6M | −$9,000 | −$12.5M | −$75.4M | −$168,000 | −$49,000 | −$5,000 | $115,000 | −$5.0M | −$170,000 | −$201,000 |
| Acquisitions & other investing | $6,000 | $58,000 | $10,000 | $1.3M | $0 | $168,000 | $49,000 | $5,000 | $115,000 | $0 | $170,000 | $201,000 |
| Cash from investing activities | −$6,000 | −$12.6M | −$9,000 | −$11.2M | −$75.4M | −$168,000 | −$49,000 | −$5,000 | $115,000 | −$5.4M | −$170,000 | −$201,000 |
| Financing activities | ||||||||||||
| Dividends paid | — | — | — | −$247,000 | — | — | −$1.8M | — | — | — | −$555,000 | — |
| Share repurchases & issuance (net) | −$161,000 | −$1.1M | −$15,000 | −$10.0M | −$36,000 | −$8.1M | −$8.6M | −$8.3M | −$2.9M | −$1.4M | −$7.0M | −$23.0M |
| Net borrowing (repayment) | −$6.2M | $13.8M | $2.4M | $13.0M | −$2.0M | −$2.0M | −$2.0M | −$2.0M | −$2.0M | −$2.0M | −$2.0M | −$1.0M |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | $0 | $0 | $0 | $494,000 | $1.5M | −$1.3M | $2.4M | $233,000 | −$355,000 | $412,000 | $3.4M | $42,000 |
| Cash from financing activities | −$6.4M | $12.6M | $2.4M | $3.3M | −$536,000 | −$11.4M | −$10.1M | −$10.0M | −$5.2M | −$3.0M | −$6.1M | −$24.0M |
| Summary | ||||||||||||
| Net change in cash | −$6.5M | −$33.4M | $39.9M | −$21.2M | −$33.0M | −$28.1M | −$2.1M | −$9.0M | $3.5M | $2.1M | $13.5M | −$18.5M |
| Cash at end of period | $15.4M | $21.9M | $55.3M | $15.4M | $36.6M | $69.5M | $97.7M | $99.7M | $108.7M | $105.2M | $103.2M | $89.7M |
| Free cash flow | −$132,000 | −$33.6M | $37.5M | −$13.2M | $43.0M | −$16.8M | $8.0M | $1.1M | $8.7M | $10.1M | $19.6M | $5.4M |
| Free cash flow margin | −0.2% | −50.6% | 61.9% | −20.1% | 58.0% | −14.5% | 19.0% | 2.7% | 18.1% | 24.5% | 39.2% | 10.9% |
| Capex / revenue | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.1% | 0.1% | 0.0% | 0.2% | 0.9% | 0.3% | 0.4% |
| Operating cash flow / net income | −0.02 | −5.83 | 4.60 | — | — | −0.38 | — | — | 2.38 | — | 2.45 | 0.80 |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
EGRX cash generation
In fiscal 2022 (ended December 31, 2022), Eagle Pharmaceuticals generated $50.7 million of cash from operations (up 79.7%) and spent $0.2 million on capital expenditures, leaving free cash flow of $50.5 million, 16.0% of revenue. It returned $19.8 million to shareholders through dividends ($1.7 million) and net share buybacks ($18.0 million). Cash and equivalents fell by $42.3 million over the year.
Related: EGRX income statement, EGRX balance sheet. See the EGRX stock overview for the latest quote and news.
EGRX cash flow FAQ
What is Eagle Pharmaceuticals's free cash flow?
Eagle Pharmaceuticals's free cash flow was $50.5 million in fiscal 2022: $50.7 million of operating cash flow minus $0.2 million of capital expenditures It was $27.9 million a year earlier..
How much cash does Eagle Pharmaceuticals generate from operations?
Eagle Pharmaceuticals generated $50.7 million of cash from operating activities in fiscal 2022, 1.42 times its net income of $35.6 million.
How much does Eagle Pharmaceuticals spend on capital expenditures?
Eagle Pharmaceuticals spent $0.2 million on capital expenditures in fiscal 2022, 0.1% of revenue, compared with $0.3 million the year before.
How much stock does Eagle Pharmaceuticals buy back?
Eagle Pharmaceuticals spent $18.0 million on net share repurchases in fiscal 2022.
How much does Eagle Pharmaceuticals pay in dividends?
Eagle Pharmaceuticals paid $1.7 million in dividends in fiscal 2022, 3.5% of free cash flow.